EP0511767A1 — Tablets containing compound DUP753
Assigned to Merck and Co Inc · Expires 1992-11-04 · 34y expired
What this patent protects
An optimized direct compression tablet formulation comprises in parts by weight from about 10% to about 45% of 2-butyl-4-chloro-1[(2'(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-5-(hydro xymethyl)-imidazole, from about 20% to about 40% microcrystalline cellulose, from about 10% to abo…
USPTO Abstract
An optimized direct compression tablet formulation comprises in parts by weight from about 10% to about 45% of 2-butyl-4-chloro-1[(2'(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-5-(hydro xymethyl)-imidazole, from about 20% to about 40% microcrystalline cellulose, from about 10% to about 30% lactose, from about 0.5% to about 0.9% magnesium stearate, and from about 5% to about 35% pregel starch.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.